Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 11/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TOP2A | P11388 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL608845 | 0.95 | FGFR1 (0.47) | FGFR1PSMB5NPC1MEN1KMT2A | |
| SCHEMBL608846 | 0.95 | FGFR1 (0.47) | FGFR1PSMB5NPC1MEN1KMT2A | |
| Lysine SCHEMBL16061827 | 0.92 | FGFR1 (0.44) | FGFR1PSMB5NPC1MEN1KMT2A | |
| SCHEMBL608515 | 0.84 | FGFR1 (0.34) | FGFR1PSMB5NPC1 | |
| SCHEMBL608516 | 0.84 | FGFR1 (0.34) | FGFR1PSMB5NPC1 | |
| SCHEMBL626166 | 0.81 | PSMB5 (0.58) | FGFR1PSMB5NPC1MEN1KMT2A | |
| SCHEMBL626167 | 0.81 | PSMB5 (0.58) | FGFR1PSMB5NPC1MEN1KMT2A | |
| SCHEMBL13341572 | 0.81 | PSMB5 (0.49) | FGFR1PSMB5NPC1MEN1KMT2A | |
| SCHEMBL10061382 | 0.80 | CCR6 (0.39) | NPC1KMT2AHPGD | |
| SCHEMBL18569805 | 0.78 | MEN1 (0.51) | FGFR1NPC1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040976-A1 | SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040976-A1 | SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE | L1CAM, LY96, GMFG | FGFR1 4281/4885PSMB5 1264/4885NPC1 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.